Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Kymera Therapeutics Inc. (KYMR)

NASDAQ: KYMR · Biological Products, (No Diagnostic Substances) · Watertown, MA

Our rating: Neutral

Neutral reaffirmed at $126.63, moderate conviction, October 30, 2026.

Breaks if: Turns Cautious if reported collaboration revenue falls below $20 million over any rolling four quarters — signaling that milestone and partnership economics are genuinely eroding — or if a pivotal-stage program announces a primary-endpoint miss within the next twelve months. Turns Positive if revenue recovers above $60 million annually on new milestone triggers and the free-cash-flow burn narrows to better than negative $170 million within the next four quarters.

Key figures

Market value$9.8B
Revenue, last 12 months$102M
Net income, last 12 months−$349M
Free cash flow, last 12 months−$289M
Price to earningsn/a
Free cash flow yield−2.9%
Dividend yield0.0%
Operating margin−396.0%
Return on equity−27.3%
Beta to the S&P 5001.45
Volatility, annualized68.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$0.00−100.0%$-1.32−$78M
June 30, 2026$65M466.4%$-0.62−$55M
March 31, 2026$34M55.5%$-0.71−$89M
December 31, 2025$3M−61.2%$-0.98−$67M
September 30, 2025$3M−26.1%$-0.94−$27M
June 30, 2025$11M−55.3%$-0.95−$61M
March 31, 2025$22M114.8%$-0.82−$80M
December 31, 2024$7M−84.6%$-0.89−$63M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 25 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.